|
Título:
|
Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
|
|
Autor/a:
|
Sánchez Rovira, Pedro; Seguí, M. A.; Llombart, A.; Aranda, Enrique; Antón, Antonio; Sánchez, A.; Lomas, M.; Jaén, A.; Fernández, M.; Porras, I.; Dalmau, E.; Morales Murillo, Serafín; Haba-Rodríguez, J. de la
|
|
Notas:
|
Purpose: The primary aim of this trial was to assess the rate of pathologic complete responses (pCR) of doxorubicin/cyclophosphamide (AC) followed by bevacizumab/docetaxel (BT), as neoadjuvant therapy for breast cancer (BC). Furthermore, the association between biomarkers and the pCR was explored.
Methods: Patients with HER-negative operable stage II–III BC ≥2 cm were enrolled. Four cycles of AC (A 60 mg/m2 and C 600 mg/m2, every 3 weeks) followed by 4 cycles of BT (B 15 mg/kg and T 75 mg/m2, every 3 weeks), were planned. A core-biopsy was performed for biological markers assessment.
Results: Seventy-two women were included. Forty-three (63 %) patients were hormone receptor-positive. Sixty-four (89 %) completed the planned treatment, and 66 evaluable patients underwent surgery (92 %): a pCR was achieved in 16 of them (24, 95 % CI 15–36 %). pCR was significantly higher in tumors hormone receptor-negative, and in those with Angiotensin II type 1 receptor (AGTR1) protein overexpression. The overall clinical response rate was 86 % (95 % CI 76–93 %), including 42 complete responses. No unexpected toxicities or treatment-related deaths were observed.
Conclusion: This regimen showed a remarkable clinical and pathological activity: the suggested relation between pCR and AGTR1 overexpression should be confirmed in larger trials.
Financial support for this research was provided by Roche Farma, S.A. |
|
Materia(s):
|
-Bevacizumab
-Biomarkers
-Breast cancer
-Combined modality therapy
-Neoadjuvant therapy |
|
Derechos:
|
cc-by (c) Sánchez-Rovira et al., 2013
http://creativecommons.org/licenses/by/4.0/
|
|
Tipo de documento:
|
Artículo
Artículo - Versión publicada |
|
Editor:
|
Springer
|
|
Compartir:
|
|
